10 October 2012 | News | By BioSpectrum Bureau
Merck Millipore enhances bioavailability portfolio
Singapore: Merck Millipore is boosting its portfolio for drug bioavailability, including products for all types of dosage forms that address solubility, and PK/PD modification and targeting, which must be taken into account for optimized bioavailability in the final drug.
These bioavailability enhancement options offer a unique blend of broad experience, deep application know-how, and cGMP production capabilities to support customers beginning with API development to registration of the final dosage form. Merck Millipore will support this portfolio through major investments in the years to come.
Bioavailability is a prerequisite for attaining the maximum efficacy of active pharmaceutical ingredients. Ensuring high levels of bioavailability in the development of a therapeutic formulation is a major challenge facing the pharmaceutical industry. To address this issue, Merck Millipore provides solutions for formulators to ensure the right amount of a drug is delivered, at the right time, to the right place in the body.
Dr Burghard Freiberg, VP, Pharm Chemicals Solutions, Merck Millipore, said that, "Because each customer's challenge requires a unique approach, we offer the broadest portfolio of excipients and technologies to improve the bioavailability of APIs and will continue to expand this portfolio. We work closely with our customers to develop optimal solutions, and through our expertise, we are able to recognize opportunities for optimization that may have otherwise gone unnoticed."
Nearly 40 percent of drug candidates fail in clinical trials due to poor bioavailability properties. Avoiding these failures can help control skyrocketing drug development costs, reduce wasted time and resources, and accelerate the development process. Enhancement of bioavailability can boost pipeline productivity, secure return on investment and enable more effective life-cycle management. Additionally, it can also help differentiate and drive cost reduction of current therapeutics.